Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00129259
Status:
COMPLETED
Last Update Posted:
2017-05-22
First Post:
2005-08-09
Brief Title:
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Phase II Multiple-Dose Treatment of New Onset Type 1 Diabetes Mellitus With Anti-CD3 mAb
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AbATE
Brief Summary:
Anti-CD3 monoclonal antibody aka hOKT3gamma1 Ala-Alateplizumab MGA031 is a humanized antibody that is commonly used to prevent organ rejection The purpose of this study is determine whether anti-CD3 mAb treatment can halt the progression of newly diagnosed type 1 diabetes
Detailed Description:
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks insulin-producing beta cells in the pancreas Without these cells the body cannot maintain proper blood glucose levels in response to daily activities such as eating or exercise Generally at the time of type 1 diabetes diagnosis 60 to 85 of the diabetic persons beta cells have already been destroyed However between 15 and 40 of these cells remain and are able to produce insulin Treatment that slows the destruction of additional beta cells may be able to decrease a patients reliance on insulin and improve their quality of life
Anti-CD3 mAb is genetically engineered and directed against the CD3 antigen on T cells this antibody selectively attacks the immune cells responsible for beta cell destruction In a small exploratory clinical trial patients with newly diagnosed type 1 diabetes who received a single 2-week treatment with anti-CD3 mAb had preserved beta cell function and significantly lower insulin requirements than untreated patients for up to two years after therapy This study will investigate whether a second course of anti-CD3 mAb administered one year after the first administration is able to prolong or improve the effects of the biologic in people who have recently diagnosed type 1 diabetes mellitus
Participants will be randomly assigned to one of two groups The Experimental Group will receive anti-CD3 mAb treatment plus Diabetes Standard of Care Treatment the Active Comparator Group will receive Diabetes Standard of Care Treatment The Experimental Group will be treated with the antibody for the first 14 days of the study and again one year later These participants will be admitted to the hospital for the first 5 days of a treatment cycle Participants who live within 1 hour of the hospital may receive the remainder of a treatment cycle as an outpatient but those who live farther away will be hospitalized for 14 days For the first treatment cycle there will be study visits on the 3 consecutive days after the treatment cycle and at Months 1 2 3 6 9 and 12 For the second treatment cycle there will be study visits on the 3 consecutive days after the treatment cycle and at Months 13 16 19 21 and 24The Active Comparator Group will have 12 study visits over two years
At study entry all participants will receive daily iron supplementation either as ferrous sulfate or a multivitamin with iron Participants will be followed for up to 2 years to assess their overall diabetes health and to capture laboratory measures of beta cell and immune system function Medication history and adverse event assessment will occur at all visits A physical exam vital signs measurement and blood collection will occur at most visits Medical history and urine collection will occur at selected visits
Anti-CD3 mAb is genetically engineered and directed against the CD3 antigen on T cells this antibody selectively attacks the immune cells responsible for beta cell destruction In a small exploratory clinical trial patients with newly diagnosed type 1 diabetes who received a single 2-week treatment with anti-CD3 mAb had preserved beta cell function and significantly lower insulin requirements than untreated patients for up to two years after therapy This study will investigate whether a second course of anti-CD3 mAb administered one year after the first administration is able to prolong or improve the effects of the biologic in people who have recently diagnosed type 1 diabetes mellitus
Participants will be randomly assigned to one of two groups The Experimental Group will receive anti-CD3 mAb treatment plus Diabetes Standard of Care Treatment the Active Comparator Group will receive Diabetes Standard of Care Treatment The Experimental Group will be treated with the antibody for the first 14 days of the study and again one year later These participants will be admitted to the hospital for the first 5 days of a treatment cycle Participants who live within 1 hour of the hospital may receive the remainder of a treatment cycle as an outpatient but those who live farther away will be hospitalized for 14 days For the first treatment cycle there will be study visits on the 3 consecutive days after the treatment cycle and at Months 1 2 3 6 9 and 12 For the second treatment cycle there will be study visits on the 3 consecutive days after the treatment cycle and at Months 13 16 19 21 and 24The Active Comparator Group will have 12 study visits over two years
At study entry all participants will receive daily iron supplementation either as ferrous sulfate or a multivitamin with iron Participants will be followed for up to 2 years to assess their overall diabetes health and to capture laboratory measures of beta cell and immune system function Medication history and adverse event assessment will occur at all visits A physical exam vital signs measurement and blood collection will occur at most visits Medical history and urine collection will occur at selected visits
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None